Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Designing immune-evasive ucar-T cells to overcome allogeneic barriers and advance off-the-shelf immunotherapy

jiabiao hu, Yanan Yue, tianying chen, lina zhou, xiaomeng Bian, xiaobin song, huan chen, xu feng, yuqing lin, yixuan zhou, yingyong xu, Jianxiang Wang, Ying Wang, george church, Luhan Yang

Blood (2025) 146 (Supplement 1): 1045.

https://doi.org/10.1182/blood-2025-1045

Published: 2025

Journal Articles

Engineering Quiescent Viral Entry Pathways for in Vivo CAR-T Generation via Binder-Fusogen Combinatorics

xiaoling wang, wancheng yang, kaiyuan wang, Jiapan Hu, yixuan zhou, Ying Wang, yingyong xu, Jianxiang Wang, Jeremy Luban, Luhan Yang

Blood (2025) 146 (Supplement 1): 2404.

https://doi.org/10.1182/blood-2025-2404

Published: 2025

Journal Articles

Rapid normalization of platelet counts in patients with refractory thrombocytopenia associated with systemic lupus erythematosus (SLE) following treatment with allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B)

Blood (2025) 146 (Supplement 1): 3031.

https://doi.org/10.1182/blood-2025-3031

Published: 2025

Journal Articles

Enhanced vsvg variants for binder‑dependent and high‑specificity transduction of primary T cells

kaiyuan wang, xiaoling wang, wancheng yang, Jiapan Hu, yixuan zhou, qi zhang, xuqiang kong, hao wang, peng zhang, yingyong xu, Jianxiang Wang, Ying Wang, Luhan Yang

Blood (2025) 146 (Supplement 1): 4181.

https://doi.org/10.1182/blood-2025-4181

Published: 2025

Journal Articles

Allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B) for refractory autoimmune hemolytic anemia

Blood (2025) 146 (Supplement 1): 5922.

https://doi.org/10.1182/blood-2025-5922

Published: 2025

Journal Articles

Cytokine receptor armored CAR-T cells enable robust T cell expansion and function in the absence of lymphodepletion

lina zhou, Jiapan Hu, Wancheng Yang, yixuan zhou, yinghao zhu, Fei Yang, Nian Chen, Yingyong Xu, george church, Carl June, Luhan Yang

Blood (2025) 146 (Supplement 1): 4104.

https://doi.org/10.1182/blood-2025-4104

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Designing immune-evasive ucar-T cells to overcome allogeneic barriers and advance off-the-shelf immunotherapy

Engineering Quiescent Viral Entry Pathways for in Vivo CAR-T Generation via Binder-Fusogen Combinatorics

Rapid normalization of platelet counts in patients with refractory thrombocytopenia associated with systemic lupus erythematosus (SLE) following treatment with allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B)

Enhanced vsvg variants for binder‑dependent and high‑specificity transduction of primary T cells

Allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B) for refractory autoimmune hemolytic anemia

Cytokine receptor armored CAR-T cells enable robust T cell expansion and function in the absence of lymphodepletion

Email alerts

ASH Publications

American Society of Hematology

Update search

Designing immune-evasive ucar-T cells to overcome allogeneic barriers and advance off-the-shelf immunotherapy

Engineering Quiescent Viral Entry Pathways for in Vivo CAR-T Generation via Binder-Fusogen Combinatorics

Rapid normalization of platelet counts in patients with refractory thrombocytopenia associated with systemic lupus erythematosus (SLE) following treatment with allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B)

Enhanced vsvg variants for binder‑dependent and high‑specificity transduction of primary T cells

Allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B) for refractory autoimmune hemolytic anemia

Cytokine receptor armored CAR-T cells enable robust T cell expansion and function in the absence of lymphodepletion

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only